Investors
Predictive Technology Group, Inc.
Business Description
Predictive Technology Group, Inc. (PRED) through its wholly owned subsidiary Predictive Therapeutics, Inc. revolutionizes the treatment of serious and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics. The Company has developed and/or acquired a number of proprietary technologies that open a window into the origin of human disease and the role that genes and their related proteins play in the disease’s onset and progression. PRED uses this information as the cornerstone in the development of new diagnostics that assess a person’s risk of disease and therapeutic products designed to effectively prevent and/or treat the disease.
FINANCIAL REPORTING/DISCLOSURE
| Reporting Status | Alternative Reporting Standard |
| Audited Financials | Unaudited |
| Latest Report | Sept. 30, 2017 – Quarterly Report |
| CIK | 0001382943 |
| Fiscal Year End | 06/30 |
| OTC Marketplace | OTC Pink Current |
PROFILE DATA
| SIC – Industry Classification | 2835 – Diagnostic substances |
| Business Status | Development Stage Company a/o Sep 16, 2008 |
| Incorporated In: | NV, USA |
| Year of Inc. | 2005 |
| Employees | 27 a/o Oct. 31, 2017 |
COMPANY OFFICERS/CONTACTS
| Merle Ferguson | Secretary, Treasurer |
| Bradley Robinson | President |
COMPANY DIRECTORS
| Merle Ferguson | Chairman |
| Bradley Robinson | Director |
